Stockreport

Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade [Seeking Alpha]

Benitec Biopharma Inc.  (BNTC) 
US:NASDAQ Investor Relations: benitec.com/for-investors/investor-faqs
PDF Their mechanism of action works through an AAV "silence-and-replace" approach (silence the mutant gene and replace it with a functional copy). BNTC's Phase 1b/2a Coho [Read more]